-5%
Adrinor Injection (Adrenaline/Epinephrine) | Anaphylaxis management, Mydriatic and Cycloplegic agents, Adrenoceptor stimulants, Respiratory stimulants
Pregnancy Category C: Use only if benefits justify the potential risk.
Excreted in breast milk; not recommended during lactation due to possible effects on infants.
Adrinor is a fast-acting sympathomimetic agent that acts directly on alpha and beta-adrenergic receptors. It is primarily used in cardiopulmonary resuscitation (CPR) and the emergency treatment of anaphylaxis, severe asthma, and cardiac arrest. It enhances cardiac output, increases blood pressure and heart rate, promotes bronchodilation, raises blood glucose levels, and reduces inflammatory responses caused by histamines.
Adrinor (epinephrine) stimulates both alpha- and beta-adrenergic receptors:
- Alpha-1 effects: Vasoconstriction leading to increased systolic blood pressure.
- Beta-1 effects: Enhanced heart rate and contractility.
- Beta-2 effects: Bronchodilation and metabolic effects (e.g., increased blood glucose).
Pharmacokinetics
- Onset: Rapid
- Half-life: 5–10 minutes
- Metabolism: Liver (MAO and COMT)
- Excretion: ~90% via urine as metabolites
- Protein Binding: ~50%